Immunity induced by Staphylococcus aureus surface protein A was protective against lethal challenge of Staphylococcus aureus in BALB/c mice

Abstract

Staphylococcus aureus is the most common cause of hospital‐acquired bacteremia. Due to emergence of antibiotic‐resistant strains, these infections present a serious public health threat. In this study, to develop a broadly protective vaccine, we tested whether immune responses induced by several proteins associated with S. aureus toxicity could protect mice from lethal challenge with human clinical S. aureus isolate USA300. We found that the surface protein A (SasA) of S. aureus could protect mice from lethal challenge of the bacteria.

Monoclonal Antibody Targeting Staphylococcus aureus Surface Protein A (SasA) Protect Against Staphylococcus aureus Sepsis and Peritonitis in Mice

“…SasA is composed of 2,271 amino acids and belongs to the serine-rich repeat proteins (SRRPs) family [ 21 ]. Consistent with a previous report that SRRPs are potential vaccine candidates [ 21 ], active immunization with SasA can induce a specific antibody response and protect BALB/c mice against staphylococcal lethal challenge [ 22 ]. Of note, SasA is prevalent among clinical S .…”

Protection against Staphylococcus aureus and tetanus infections by a combined vaccine containing SasA and TeNT-Hc in mice

“…The antigens used in the current study were expressed in E. coli BL21 (DE3) and purified to >90%. The purification protocols were the same as described previously (9,16). Briefly, the polyhistidine-tagged recombinant SasA (rSasA) was purified by anion exchange, HisTrap and gel filtered chromatography (GE Healthcare Bio-Sciences, Pittsburgh, PA, USA).…”

“…In the present study, mice were immunized with a combined vaccine consisting of SasA (9) and TeNT-Hc (16) formulated by adsorption to Alhydrogel. The antibody titers and protective efficacy were measured for individual and combined vaccine administrations.…”

“…Those susceptible to trauma, including athletes, soldiers and the police, as well as women of childbearing age in developing countries, may benefit from the development of a combined vaccine against S. aureus and tetanus infections. S. aureus surface protein A (SasA), a cell wall-anchored protein of S. aureus, consisting of 2,271 amino acid residues, is a potential vaccine candidate for S. aureus infections (9). SasA has been reported to be a virulence determinant in endovascular infections, as the SasA mutant strain was observed to decrease the ability of catheterized rabbits to form vegetative plaques on heart valves (10).…”

“…In addition, SasA is prevalent in S. aureus clinical isolates, and is expressed during in vivo growth of the bacteria (11). Notably, immunization with SasA was able to protect mice against a lethal S. aureus challenge (9). The tetanus toxin is a 150 kDa protein that has three domains (12), including the N-terminal zinc endopeptidase domain (13), the internal heavy chain translocation domain and the C-terminal heavy chain receptor-binding domain known as the C-fragment of tetanus neurotoxin (TeNT-Hc) (14).…”